Filing Details
- Accession Number:
- 0001415889-21-002957
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-11 16:30:07
- Reporting Period:
- 2021-06-10
- Accepted Time:
- 2021-06-11 16:30:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750284 | Olema Pharmaceuticals Inc. | OLMA | Pharmaceutical Preparations (2834) | 300409740 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1831215 | Kinney Horn | C/O Olema Pharmaceuticals, Inc. 512 2Nd Street, 4Th Floor San Francisco CA 94107 | Chief Business Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-06-10 | 5,251 | $2.06 | 7,041 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-06-10 | 300 | $28.30 | 6,741 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-06-10 | 2,164 | $29.60 | 4,577 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-06-10 | 2,787 | $29.97 | 1,790 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-06-10 | 5,251 | $0.00 | 5,251 | $2.06 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 189,046 | 2030-06-09 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The weighted average sale price for the transaction reported was $28.30, and the range of prices were between $27.79 and $28.63. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $29.60, and the range of prices were between $28.81 and $29.80. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $29.97, and the range of prices were between $29.82 and $30.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.
Billionaire Hedge Funds
